Cargando…
Chemokine receptors: multifaceted therapeutic targets
Chemokines and their receptors are involved in the pathogenesis of diseases ranging from asthma to AIDS. Chemokine receptors are G-protein-coupled serpentine receptors that present attractive tractable targets for the pharmaceutical industry. It is only ten years since the first chemokine receptor w...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097668/ https://www.ncbi.nlm.nih.gov/pubmed/11910892 http://dx.doi.org/10.1038/nri722 |
_version_ | 1783511033560694784 |
---|---|
author | Proudfoot, Amanda E. I. |
author_facet | Proudfoot, Amanda E. I. |
author_sort | Proudfoot, Amanda E. I. |
collection | PubMed |
description | Chemokines and their receptors are involved in the pathogenesis of diseases ranging from asthma to AIDS. Chemokine receptors are G-protein-coupled serpentine receptors that present attractive tractable targets for the pharmaceutical industry. It is only ten years since the first chemokine receptor was discovered, and the rapidly expanding number of antagonists holds promise for new medicines to combat diseases that are currently incurable. Here, I focus on the rationale for developing antagonists of chemokine receptors for inflammatory disorders and AIDS, and the accumulating evidence that favours this strategy despite the apparent redundancy in the chemokine system. |
format | Online Article Text |
id | pubmed-7097668 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2002 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-70976682020-03-26 Chemokine receptors: multifaceted therapeutic targets Proudfoot, Amanda E. I. Nat Rev Immunol Article Chemokines and their receptors are involved in the pathogenesis of diseases ranging from asthma to AIDS. Chemokine receptors are G-protein-coupled serpentine receptors that present attractive tractable targets for the pharmaceutical industry. It is only ten years since the first chemokine receptor was discovered, and the rapidly expanding number of antagonists holds promise for new medicines to combat diseases that are currently incurable. Here, I focus on the rationale for developing antagonists of chemokine receptors for inflammatory disorders and AIDS, and the accumulating evidence that favours this strategy despite the apparent redundancy in the chemokine system. Nature Publishing Group UK 2002 /pmc/articles/PMC7097668/ /pubmed/11910892 http://dx.doi.org/10.1038/nri722 Text en © Nature Publishing Group 2002 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Article Proudfoot, Amanda E. I. Chemokine receptors: multifaceted therapeutic targets |
title | Chemokine receptors: multifaceted therapeutic targets |
title_full | Chemokine receptors: multifaceted therapeutic targets |
title_fullStr | Chemokine receptors: multifaceted therapeutic targets |
title_full_unstemmed | Chemokine receptors: multifaceted therapeutic targets |
title_short | Chemokine receptors: multifaceted therapeutic targets |
title_sort | chemokine receptors: multifaceted therapeutic targets |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097668/ https://www.ncbi.nlm.nih.gov/pubmed/11910892 http://dx.doi.org/10.1038/nri722 |
work_keys_str_mv | AT proudfootamandaei chemokinereceptorsmultifacetedtherapeutictargets |